Inventor
MARKLAND WILLIAM
US30 patents
⚠️ This page may combine multiple inventors who share the name “MARKLAND WILLIAM”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
DYAX CORP
19 patentsUS6423498B1Jul 23, 2002
Variegated Kunitz domain peptide library and uses thereof
DYAX CORP143 citations99
US6333402B1Dec 25, 2001
Kallikrein-binding “Kunitz domain” proteins and analogues thereof
DYAX CORP115 citations99
US6057287AMay 2, 2000
Kallikrein-binding "Kunitz domain" proteins and analogues thereof
DYAX CORP125 citations99
US6010880AJan 4, 2000
Inhibitors of human plasmin derived from the kunitz domains
DYAX CORP102 citations99
US5994125ANov 30, 1999
Kallikrein-inhibiting "Kunitz Domain" proteins and analogues thereof
DYAX CORP112 citations99
US5795865AAug 18, 1998
Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
DYAX CORP145 citations99
US7208293B2Apr 24, 2007
Directed evolution of novel binding proteins
DYAX CORP94 citations98
US7118879B2Oct 10, 2006
Method of recovering a nucleic acid encoding a proteinaceous binding domain which binds a target material
DYAX CORP80 citations98
US6979538B2Dec 27, 2005
Directed evolution of novel binding proteins
DYAX CORP80 citations98
US5663143ASep 2, 1997
Engineered human-derived kunitz domains that inhibit human neutrophil elastase
DYAX CORP272 citations98
US6103499AAug 15, 2000
Inhibitors of human plasmin derived from the Kunitz domains
DYAX CORP79 citations97
US6071723AJun 6, 2000
Inhibitors of human plasmin derived from the Kunitz domains
DYAX CORP78 citations97
US5837500ANov 17, 1998
Directed evolution of novel binding proteins
DYAX CORP595 citations97
US7919462B2Apr 5, 2011
Inhibitors of human plasmin derived from the Kunitz domains
DYAX CORP29 citations96
US7628983B2Dec 8, 2009
Kallikrein-binding “Kunitz domain” proteins and analogues thereof
DYAX CORP48 citations96
US6953674B2Oct 11, 2005
Inhibitors of human plasmin derived from the kunitz domains
DYAX CORP31 citations96
US7893007B2Feb 22, 2011
Directed evolution of novel binding proteins
DYAX CORP22 citations92
US7413537B2Aug 19, 2008
Directed evolution of disulfide-bonded micro-proteins
DYAX CORP40 citations92
US7078383B2Jul 18, 2006
ITI-D1 Kunitz domain mutants as HNE inhibitors
DYAX CORP28 citations92
VERTEX PHARMA
4 patentsUS7383135B1Jun 3, 2008
Methods of designing inhibitors for JNK kinases
VERTEX PHARMA9 citations81
US11980633B2May 14, 2024
Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
VERTEX PHARMA0 citations54
US11110108B2Sep 7, 2021
Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
VERTEX PHARMA1 citations54
US8002891B2Aug 23, 2011
Crystallization of C-Jun N-Terminal Kinase 3 (JNK3)
VERTEX PHARMA0 citations49
PROTEIN ENG CORP
3 patentsMARKLAND WILLIAM
3 patentsUS8283321B2Oct 9, 2012
Kallikrein-binding “Kunitz domain” proteins and analogues thereof
MARKLAND WILLIAM38 citations95
US8663629B2Mar 4, 2014
Kallikrein-binding “kunitz domain” proteins and analogues thereof
MARKLAND WILLIAM0 citations51
US8431359B2Apr 30, 2013
Nucleic acids encoding polypeptide inhibitors of human plasmin derived from the Kunitz domains
MARKLAND WILLIAM0 citations51